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1. Introduction
The National Kidney Disease Education Program recommends using either the Cockcroft–
Gault creatinine clearance (CLCG) or Modification of Diet in Renal Disease (MDRD) equation
when determining dosages of drugs that are primarily eliminated by the kidneys [1]. Both
methods attempt to better predict creatinine clearance (CLCR) or glomerular filtration rate
(GFR) by taking into account different variables such as age, weight, gender, race, and se‐
rum creatinine (SCr), however neither equation captures the key factor of paraplegia. Over
time, individuals with paraplegia develop low SCr concentrations relative to their actual
CLCR due to significantly reduced muscle mass as a result of chronic immobility and muscle
atrophy. Both Cockcroft–Gault (CG) and MDRD formulas have SCr in their denominator in‐
versely proportional to CLCR or GFR, therefore low SCr in paraplegia would result in gross
overestimation of their renal function. Based on falsely high CLCR or GFR, clinicians could
potentially prescribe renally eliminated medications at dosages higher than recommended,
resulting in undesirably high drug concentrations leading to drug toxicity and/or adverse
drug reactions (ADRs). For example, supratherapeutic vancomycin and aminoglycosides
(AG) serum concentrations, especially if combined with other nephrotoxic and/or ototoxic
medications, could drastically increase the risk of nephrotoxicity and/or ototoxicity. This
could be devastating to many individuals with paraplegia who have existing renal insuffi‐
ciency.
In addition to high prevalence of traditional risk factors for CKD such as advanced age, dia‐
betes, hypertension, and cardiovascular disease, individuals with paraplegia have elevated
incidence of recurrent and chronic urinary tract infections, neurogenic bladder dysfunction,
and nephrolithiasis that put them at risk for developing CKD [2-6]. Fischer et al. conducted
cross-sectional analyses of data on 9333 Veterans with spinal cord injury and disorder
(SCI/D) and found that the prevalence of CKD in SCI/D was approximately 35%, considera‐
bly higher based on the modified MDRD for SCI/D than 10% based on the original MDRD
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formula [7]. Underrecognition of CKD in paraplegia makes it more crucial to use accurate
tools to estimate renal function in this population.
Currently, there is no accepted standard method for determining renal dosing regimens for
patients with paraplegia, and data on estimating renal function in such population is scarce.
However clearance of drugs primarily eliminated by the kidneys such as vancomycin and AG
nearly mirror that of the creatinine, hence could be used to assess renal function in paraplegia.
The aims of this chapter are: (1) to review the current literature on assessing renal function in
paraplegia, (2) to evaluate different methods of estimating CLCR or GFR compared with patient-
specific vancomycin and AG clearance (CLDRUG) in individuals with paraplegia, (3) to assess
whether there is a difference in the estimation of renal function between the two anatomical
degrees of SCI/D when compared with CLDRUG, and (4) to present the “Spinal Cord Injury
Equation” that more accurately estimates renal function in paraplegia.
2. Review of the current literature on assessing renal function in paraplegia
Tables 1 and 2 show, respectively, comparison of equations to predict CLCG or GFR from SCr
and review of the current literature on assessing renal function in paraplegia. Each equation
and study will be discussed in detail below.
Equation 1: Cockcroft-Gault equation (CLCG) [8]
GFR = CLCR (mL/min) = [(140 – age) x IBW in kg] / (72 x SCr); (multiply 0.85 for females)
Equation 2: Modified Cockcroft-Gault equation (CLM) [16]
GFR = CLCR (mL/min) = [(140 – age) x IBW in kg] / (72 x SCr); (multiply 0.85 for females)
SCr rounded to 1 mg/dL for patients with SCr < 1 mg/dL while using the actual SCr for
patients with SCr ≥ 1 mg/dL
Equation 3: MDRD equation [11-13*]
GFR (mL/min/1.73 m2) = 175 x standardized SCr-1.154 x age-0.203 x 1.212 (if black) x 0.742 (if female)
Equation 4: CKD-EPI equation [14*]
GFR (mL/min/1.73 m2) = 141 x min (SCr/ĸ, 1)α x max (SCr/ĸ, 1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black]
where ĸ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the
minimum of SCr/ĸ or 1, & max indicates the maximum of SCr/ĸ or 1.
Equation 5: 24-Hour endogenous creatinine clearance (CL24H ) [8]
GFR = CL24H (mL/min) = [urine creatinine x urine volume (mL)] / [SCr x time (hours) x 60]
*To enable the expression of comparisons among different methods in the same unit (mL/min), GFR values normal‐
ized to a BSA of 1.73 m2 need to be converted to uncorrected values.
Table 1. Comparison of Equations to Predict Creatinine Clearance (CLCR) or Glomerular Filtration Rate (GFR) from
Serum Creatinine Concentration
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Characteristics Macdi-armid
et al. (2000)
[9]
Mirah-madi et
al. (1983) [10]
Chikka-
lingaiah et al.
(2010) [15]
Lee and Dang
(2011) [16]
Lavezo et al.
(1995) [18]
Lee and
Yang
(2013) [19]
SCI/D:
Paraplegics (P)
Tetraplegics (T)
Non-SCI/D (control)
36
25
11
--
58
22
36
22
116
64
52
--
141
52
89
--
14
--
--
14
87
54
33
--
Age (yr.)
(mean ± SD)
38
(24-68)
P: 48 ± 17
T: 47 ± 14
63 ± 1 66 ± 11 53 ± 12 65 ± 16
Male (n [%]) -- SCI/D:
58 [100]
Control:
11 [50]
140 [99] 87 [100]
Race (n [%])
White and other
Black
-- -- 75 [65]
41 [35]
71 [82]
16 [18]
BMI (kg/m2) (mean ±
SD)
-- -- 25 ± 6 27 ± 5
CLCG (mL/min) (mean
[SD])
P: 82 ± 46
T: 70 ± 23
91 ± 37 63 ± 26 93 ± 47
MDRD GFR (mL/min/
1.73 m2) (mean ± SD)
-- -- 76 ± 33
SCr (mg/dL) (mean ±
SD)
-- P: 1 ± 0.4
T: 0.8 ±
0.3
0.74 ± 0.29 SCI/D:
0.8 ± 0.4
Control:
1.1 ± 0.3
0.88 ± 0.40
Methodology CLCG vs. CL24H
vs. mea-
sured CLCR by
99mTc-DTPA
CLCG vs. CL24H CLCG vs. CL24H vs.
MDRD
CLCG vs. CLM vs.
CL24H vs. MDRD
vs. CKD-EPI
SCI/D vs. Non-
SCI/D CLVANCO
CLSCI vs. CLCG
vs. CLM vs.
CL24H vs.
MDRD vs.
CKD-EPI
Findings/
Recommen-dations
CL24H more
accurate than
CLCG
Correction
factor: 0.8 for
paraplegic
0.6 for tetraple-
gic
Correction
factor: 0.7 for
MDRD
0.8 for CLCG
All methods
over-estimate
CLDRUG (P<
0.001).
Devel-opment
of CLSCI
↑half-life in
SCI/D
Verifi-cation
of CLSCI: CLSCI
un-biased
and more
precise.
Table 2. Review of the Current Literature on Assessing Renal Function in Paraplegia
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a. The Cockcroft-Gault (CG) equation (CLCG)
CLCG(mL/min) = (140 – age) x IBW in kg / (72 x SCr);
(multiply 0.85 for females)
The CG equation was derived from a study of 236 males aged 18-92 years based on their 24-
hour creatinine excretion. Since the publication in 1976, it has been exclusively used to estimate
CLCR based on SCr to calculate dosing regimens for renally cleared medications including
vancomycin and AG. However it may not extrapolate to individuals with paraplegia because
the CG study excluded 31 patients with 24-h creatinine excretion < 10 mg/kg, and it didn’t
reveal whether the study population included paraplegia and to what extent [8].
The review of current literature reports significant overestimation of renal function by CLCG,
thus does not recommend using the original equation in paraplegia [9-10].
Macdiarmid et  al.  studied 25 paraplegic  and 11 tetraplegic  patients  and sought to com‐
pare their CLCG and 24-hour endogenous creatinine clearance (CL24H) to the measured CLCR
by 99mTc-DTPA clearance technique [9].  The investigators found that the CG method did
not correlate well with that of the CL24H (r=0.426) or 99mTc-DTPA clearance (r=0.366) [9]. The
mean difference between CLCG and CL24H was 41.9%, and the difference between CLCG and
99mTc-DTPA clearance 50.7% where CG formula overestimated CLCR [9]. On the other hand,
the difference between CL24H  and 99mTc-DTPA clearance was 17.7% with good correlation
(r=0.71) [9].  The authors concluded that the CG formula significantly overestimates CLCR
thus not recommended, however CL24H is an accurate method of determining renal function
in paraplegia [9].
A study by Mirahmadi et al. investigated 58 male hospitalized patients with SCI/D and 22
ambulatory subjects, and compared their measured CL24H by autoanalyzer method versus
the predicted by CLCG [10]. The authors found that the predicted CLCG and measured CL24H
values closely matched in the ambulatory group while the predicted values consistently
exceeded the measured values in SCI/D [10]. Between the two anatomical degrees of SCI/D,
the paraplegic group had a markedly higher SCr (1.0 ± 0.4 mg/dL) and 24-hour urinary
creatinine excretion (16 ± 9 mg/kg) compared to the tetraplegic group where the respec‐
tive values were 0.8 ± 0.3 mg/dL and 11 ± 4.6 mg/kg [10]. The authors modified the original
CG  formula  using  a  correction  factor  of  0.8  for  paraplegics  and  0.6  for  tetraplegics  to
overcome  significant  overestimation  by  CLCG  [10].  The  correction  factors  improved  the
accuracy and precision of the predicted CLCG shown by the difference between the predicted
and measured CLCR  approaching zero and the slope of  a  linear  correlation between the
predicted and measured values approaching one with decreased Y-intercept values (p <
0.01) [10].
b. The MDRD equation (MDRD)
4-Variable MDRD:
GFR (mL/min/1.73 m2) = 175 x standardized SCr-1.154 x age-0.203 x 1.212 (if black) x 0.742 (if female)
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A more recently developed MDRD has been widely used to estimate GFR in the nephrology
arena. It is one of the two equations recommended by The National Kidney Disease Education
Program for drug dosing [1].
The MDRD equation was derived from a study of a relatively young non- paraplegic popula‐
tion (mean age 51±13 years) with chronic kidney disease, primarily to stage kidney disease
[11-12]. The original 6-variable MDRD formula integrates patient parameters including age,
gender, race, blood urea nitrogen (BUN), SCr, and serum albumin [11-12]. The performance
of this equation can be limited by variability among clinical laboratories in calibrating SCr
assays [13]. Thus, the formula was re-expressed as the 4-variable MDRD equation based on
standardized SCr assays as shown above [13]. Despite SCr calibration, the accuracy of the
equation remains compromised at levels of GFR >60 mL/min/1.73 m2 [12-14]. Nevertheless,
MDRD stands useful for GFR <60 mL/min/1.73 m2 in non- paraplegia and is endorsed by the
National Kidney Disease Foundation for estimating GFR in CKD patients [1, 11-12].
Chikkalingaiah et al. compared the performance of the 4-variable MDRD and CG equations
with CL24H in 64 patients with chronic paraplegia of greater than 6 months duration and stages
II-V CKD [15]. Precision and bias of MDRD and CG formulas were measured by combined
root mean square error (CRMSE) calculated as the square root of [(mean difference of estimated
GFR and measured CL24H)2 + (SD of the difference)2]. Respective CRMSE values for original
MDRD and CG equations were 29 and 19.3 mL/min/1.73m2. In order to improve the perform‐
ance of the prediction equations, a correction factor of 0.7 for MDRD and 0.8 for CG were
applied which resulted in a decrease in their CRMSE values to 11.4 and 13 mL/min/1.73m2,
respectively [15]. Accuracy of both prediction equations was evaluated by the percentage of
patients who did not deviate >15%, 30%, or 50% from measured CL24H. Respective percentages
for MDRD were 12.5, 25, and 48.4 before the correction, and 25, 42, 68 after the correction [15].
Respective percentages for CG were 22, 37.5, and 58 before the correction, and 25, 50, 75 after
the correction [15]. On the whole, the CG equation had less bias and was more precise and
more accurate than the MDRD equation, however still overestimated GFR in subjects with
chronic paraplegia with measured CL24H < 90 mL/min/1.73m2. Application of the correction
factors markedly improved in the overall bias, precision, and accuracy of both MDRD and CG
equations shown by both decreased CRMSE values and increased percentage of subjects in
whom GFR did not deviate >15%, 30%, or 50% from measured CL24H [15].
c. The CKD-EPI equation (CKD-EPI)
GFR (mL/min/1.73 m2) = 141 x min (SCr/ĸ, 1)α x max (SCr/ĸ, 1)-1.209 x 0.993Age x 1.018 [if female]
x 1.159 [if black]
where ĸ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min
indicates the minimum of SCr/ĸ or 1, & max indicates the maximum of SCr/ĸ or 1.
In order to overcome the known bias of the MDRD equation for GFR values of ≥60 mL/min/
1.73 m2, the researchers pooled the data from 26 studies to develop and validate a new equation,
the CKD-EPI equation, to define dose modification across the GFR range in patients with and
without CKD [14]. The data showed that the CKD-EPI equation was more precise and accurate
compared to MDRD, especially at GFR > 60 mL/min/1.73 m2, however it is not frequently used
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in current clinical practice when determining dosages of drugs that are primarily eliminated
by the kidneys due to need for further validation. Furthermore, the sample population used
to develop the CKD-EPI formula did not include paraplegia, thus its use in paraplegia may be
misleading.
d. 24-Hour endogenous creatinine clearance (CL24H)
CL24H (mL/min) = [urine creatinine x urine volume (mL)] / [SCr x time (hours) x 60]
Current literature reports that CL24H better predicts renal function compared to CLCG and
MDRD in paraplegia, however this method is not routinely utilized for drug dosing due to the
impracticability of collecting multiple urine samples as well as the propensity for error from
serial collections [8, 16].
3. Evaluation of different methods of estimating CLCR or GFR compared
with patient-specific vancomycin and aminoglycoside (AG) clearance
(CLDRUG ) in individuals with SCI/D
Data on the application of methods of estimating renal function compared with patient-specific
CLDRUG in paraplegia is scarce.
Lavezo et al. compared the pharmacokinetics of vancomycin in 14 SCI/D and 14 non-SCI/D
control patients with their age, weight, pharmacokinetic parameters of total body clearance,
volume of distribution, and mean predicted dosages matched. Demographic data between the
groups differed only in mean SCr where the values were 0.8 ± 0.4 in the SCI/D group and 1.1
± 0.3 in the able-bodied control group (p=0.04). The investigators obtained the pharmacokinetic
parameters via two steady-state vancomycin serum concentrations by the Sawchuk and Zaske
method [17] and found that compared to the control group, mean elimination rate constant
was significantly smaller, therefore mean elimination half-life significantly longer in patients
with SCI/D [18]. The authors concluded that patients with SCI/D may require longer dosing
intervals of vancomycin compared to non-SCI/D [18].
In 2011, Lee and Dang published the results of a retrospective pharmacokinetic analysis of
data on 141 patients with long-term SCI/D in the Veterans Affairs (VA) hospital with the largest
inpatient SCI center in the VA system. The investigators evaluated frequently employed
methods to estimate GFR (CLCG, modified CG, CL24H, MDRD, and CKD-EPI) against patient-
specific drug clearance of vancomycin and AG (CLDRUG) [16]. Table 3 shows that all methods
overestimate CLDRUG (p <0.001). The mean difference between CLDRUG and MDRD is largest
where overestimation by MDRD is more than two-fold. Almost 70% of the patients had
overestimation of CLDRUG by greater than 30 mL/min when using MDRD to predict empiric
dosing for vancomycin and AG (p < 0.001) [16]. The authors modified the original CG equation
by rounding SCr to 1 mg/dL for patients with SCr < 1 mg/dL while using the actual SCr for
patients with SCr ≥ 1 mg/dL in attempts to account for low SCr in SCI/D and to overcome gross
overestimation of renal function by CLCG [16]. The investigators found that the modified CG
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equation (CLM) better estimated CLDRUG in SCI/D, compared with other frequently employed
methods for predicting GFR. The mean difference between CLDRUG and CLM was smallest
among the equations evaluated where overestimation by CLM was approximately 40%. Almost
65% of the patients had prediction of CLDRUG within 30 mL/min when using CLM to estimate
empiric dosing for vancomycin and AG (p < 0.001) [16]. Despite pronounced improvement by
modification of CG, overestimation may not be clinically acceptable.
(N=141) Mean ± S.D.(mL/min) Difference from CLDRUG (mL/min) P-Value
CLDRUG 49.77 ± 19.97 0 --
MDRD 119.76 ± 61.49 69.99 <0.001
CKD-EPI 90.71 ± 27.44 40.94 <0.001
CL24H 85.16 ± 33.88 35.39 <0.001
CLCG 91.24 ± 36.90 41.47 <0.001
CLM 69.38 ± 13.49 19.61 <0.001
Abbreviations: GFR, glomerular filtration rate; CLDRUG, actual drug clearance; MDRD, the Modification of Diet in Renal
Disease equation; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; CL24H, 24-hour endogenous
creatinine clearance; CLCG, the Cockcroft-Gault formula; CLM, modified Cockcroft-Gault formula; S.D., standard devia‐
tion. Published with permission of Lee [16].
Table 3. Evaluation of Different Methods to Estimate GFR
4. Estimation of renal function between the two anatomical degrees of SCI
when compared with CLDRUG
As previously mentioned, Mirahmadi et al. reported that both SCr and mean urinary creatinine
excretion were markedly lower in paraplegics compared with ambulatory subjects [10]. The
authors recommended an adjustment of the original CG equation by 20% for paraplegics to
correct for reduction of muscle mass relative to the total body weight in such population [10].
Chikkalingaiah et al. found that both prediction equations (MDRD and CG) overestimated
GFR in the paraplegic group with an overestimation by MDRD to a higher degree [15]. The
fractional prediction error (FPE = (variable 1-variable 2) x 100/variable 1) for MDRD and CG
were, respectively, 48.5% and 29.5% for paraplegic subjects, where an FPE greater than 20%
was considered to be clinically unacceptable [15]. A correction factor of 0.7 for MDRD and 0.8
for CG proposed by the authors decreased the FPE to 3.9% and 3.6%, respectively, for the
paraplegic group [15].
Lee and Dang sought to evaluate various methods to predict CLDRUG for different anatomical
degrees of SCI/D (Table 4) [16]. The mean difference between CLSCI and CLDRUG was not
statistically significant when separated into paraplegia and tetraplegia [16]. Similar finding
was noted for CLM and CL24H [16]. On the other hand, the mean differences between CLCG,
CKD-EPI, and MDRD and CLDRUG were statistically significant between the two anatomical
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degrees of SCI where tetraplegics had a gross overestimation of CLDRUG compared with
paraplegics [16]. The investigators stated that such difference may have risen from rounding
SCr up to 1 mg/dL for patients with SCr < 1 mg/dL and using a ratio of urine creatinine to SCr
done in CLM and CL24H, respectively, contrary to using the actual SCr in the other equations [16].
Individuals with paraplegia have variable functionality and range of mobility and movement
depending on the injury levels. Degree of paralysis of lower body and legs and upper body
strength could affect muscle mass therefore potentially alter SCr and CLCR or GFR. For
example, one with high paraplegia (>T7) may have weaker upper body strength and balance
compared to the one with low (T7-T12) paraplegia thus may have lower muscle mass and SCr
resulting in a falsely low estimation of renal function compared to the low paraplegia.
Unfortunately, there has yet been a study that assesses renal function between different
anatomical levels or severity of injury in paraplegia.
Mean Difference from CLDRUG ± S.D. (mL/min) p-Value
Paraplegics
(n = 52)
Tetraplegics
(n = 89)
CLSCI -3.11 ± 13.14 -5.39 ± 21.16 0.48
CLM 21.04 ± 13.81 18.76 ± 22.26 0.5
CL24H 32.60 ± 30.78 37.02 ± 35.29 0.45
CLCG 27.26 ± 20.56 49.76 ± 38.55 <0.001
CKD-EPI 27.52 ± 25.50 48.77 ± 24.76 <0.001
MDRD 40.68 ± 40.71 50.64 ± 64.56 <0.001
Abbreviations: CLDRUG, actual drug clearance; SCI, spinal cord injury; CLSCI, spinal cord injury equation; CLM, modified
Cockcroft-Gault formula; CL24H, 24-hour endogenous creatinine clearance; CLCG, the Cockcroft-Gault formula; CKD-EPI,
Chronic Kidney Disease Epidemiology Collaboration equation; MDRD, the Modification of Diet in Renal Disease equa‐
tion; S.D., standard deviation. Published with permission of Lee [16].
Table 4. Evaluation of Methods to Predict CLDRUG for Different Anatomical Degrees of SCI/D
5. The “Spinal Cord Injury Equation” (CLSCI)
Gross overestimation of CLDRUG by the frequently employed methods for estimating GFR
prompted the authors Lee and Dang to develop an alternative method of estimating CLDRUG
in SCI/D, the “spinal cord injury equation” (henceforth referred to as the CLSCI equation):
CLSCI (mL/min) = 2.3 X CLM 0.7
where CLSCI and CLM denote, respectively, clearance values determined via use of the CLSCI
equation and the CLM formula [16]. The CLSCI equation yields a value along the line of best fit
(the straight trend line depicting the line of least variability in all points on a scatterplot of data
derived by regression analysis of two variables) between CLM and patient-specific vancomycin
clearance (CLV) values [16].
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Figures 1 and 2 depict, respectively, plots of actual drug clearance versus modified CG
predicted drug clearance and linear regression plots of actual drug clearance versus predicted
drug clearance using the CLSCI equation [16]. The slope of a linear correlation between the
predicted and measured CLV values approach one, and the Y-intercept of a linear correlation
between the predicted and measured CLV values is minimum [16].
The CLSCI equation was tested against other methods through a retrospective analysis of 87
hospitalized patients with long-term SCI/D [19]. The study population had similar baseline
characteristics to the previous population by Lee and Dang, exclusively elderly, overweight,
males with similar SCr. The authors used the Sheiner and Beal method [20] for determining
predictive performance (precision and bias) to evaluate the predictive ability of the CLSCI
equation in estimating vancomycin clearance, relative to five alternative methods (CLCG,
modified CG, CL24H, MDRD, and CKD-EPI). Compared with other equations, the CLSCI
equation was found to be less biased and more precise, with the smallest calculated mean
prediction error (ME) and square root of the mean squared prediction error (RMSE) values (p
< 0.005) (Table 5) [19]. Predictive performance of the CLSCI relative to each of the other five
methods was measured by change in ME (relative bias between two methods) and change in
MSE (relative precision) (Table 6). Negative values for changes in ME and MSE indicate an
advantage favoring the comparator; a greater negative value signifies a greater magnitude of
error. The five alternative equations significantly overestimated CLV, by 45-92% (p < 0.05)
(Table 7) [19]. The CLSCI equation underestimated CLV by approximately 6%, however not to
a significant degree (p = 0.06) [19]. The results of their finding were consistent with the previous
study by Lee and Dang.
Figure 1. Plots of Actual Drug Clearance versus Modified Cockcroft–Gault Predicted Drug Clearance. Published with
permission of Lee [16].
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Figure 2. Linear Regression Plots of Actual Drug Clearance versus Predicted Drug Clearance Using the Spinal Cord In‐
jury Equation. The red line, y=x, represents a line with a slope of 1 that indicates a perfectly one-to-one association
between the actual and predicted drug clearance. Published with permission of Lee [16].
Parameter CLSCI CLM CL24H CKD-EPI CLCG MDRD
Bias
ME (mL/min) -3.1 21.5 32.5 33.0 44.5 47.5
95% CI
(mL/min) -6.3 to 0.1 17.8 to 25.1 26.2 to 38.8 27.7 to 38.4 36.2 to 52.7 31.2 to 55.8
Precision
MSE
(mL2/min2) 235.2 748.9 1925.2 1712.7 3450.1 3760.3
95% CI
(mL2/min2) 168.9 to 301.4 562.7 to 935.2 1191.2 to 2659.2 1271.6 to 2153.8 2334.8 to 4565.3 2640.1 to 4880.5
RMSE
(mL/min) 15.3 27.4 43.9 41.4 58.7 61.3
95% CI
(mL/min) 13.0 to 17.4 23.7 to 30.6 34.5 to 51.6 35.7 to 46.4 48.3 to 67.6 51.4 to 69.9
Abbreviations: ME, mean error; CI, confidence interval; MSE, mean squared error; RMSE, root mean squared error;
CLSCI, spinal cord injury equation; CLM, modified Cockcroft-Gault formula; CL24H, 24-hour endogenous creatinine clear‐
ance; CKD-EPI, Long-term Kidney Disease Epidemiology Collaboration equation; CLCG, the Cockcroft-Gault formula;
MDRD, the Modification of Diet in Renal Disease equation. Published with permission of Lee [19].
Table 5. Absolute Predictive Performance of Vancomycin Clearance
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ΔME (CI) (mL/min) ΔMSE (CI) (mL2/min2)
CLSCI vs. CLM -24.5 (-26.8 TO -22.3) -513.8 (-709.8 to -317.8)
CLSCI vs. CL24H -35.5 (-42.6 TO -28.5) -1690.0 (-2436.5 to -943.5)
CLSCI vs. CKD-EPI -36.1 (-41.3 TO -30.9) -1477.5 (-1922.8 to -1032.3)
CLSCI vs. CLCG -47.5 (-55.9 TO -39.1) -3214.9 (-4331.1 to -2098.7)
CLSCI vs. MDRD -50.6 (-59.1 TO -42.1) -3525.1 (-4645.0 to -2405.2)
Abbreviations: ΔME, the difference in mean errors; ΔMSE, the difference in mean squared errors; CI, confidence interval;
CLSCI, spinal cord injury equation; CLM, modified Cockcroft-Gault formula; CL24H, 24-hour endogenous creatinine clearance;
CKD-EPI, Long-term Kidney Disease Epidemiology Collaboration equation; CLCG, the Cockcroft-Gault formula; MDRD, the
Modification of Diet in Renal Disease equation. Published with permission of Lee [19].
Table 6. Relative Predictive Performance of Vancomycin Clearance
N = 87 Mean ± S.D. (ml/min) Difference from patient-specific CLV (ml/min)
p-value
CLSCI 45.2 ± 9.1 -3.1 0.06
CLM 69.7 ± 19.7 21.5 < 0.05
CL24H 82.8 ± 36.0 34.6 < 0.05
CKD-EPI 81.2 ± 30.4 33.0 < 0.05
CLCG 92.7 ± 47.0 44.4 < 0.05
MDRD 95.7 ± 45.2 47.5 < 0.05
Abbreviations: CLV, patient-specific vancomycin clearance ; S.D., standard deviation; CLSCI, spinal cord injury equation;
CLM, modified Cockcroft-Gault formula; CL24H, 24-hour endogenous creatinine clearance; CKD-EPI, Long-term Kidney
Disease Epidemiology Collaboration equation; CLCG, the Cockcroft-Gault formula; MDRD, the Modification of Diet in
Renal Disease equation. Published with permission of Lee [19].
Table 7. Evaluation of Different Methods to Estimate CLV
6. Conclusion
SCr determinations are used to estimate the dose of potentially toxic drugs eliminated
primarily by the kidneys. Due to immobility and muscle atrophy, individuals with long-
duration paraplegia have lower SCr levels relative to their CLCR; this could lead to substantial
overestimation of GFR resulting in higher than desired concentrations of medications that
increase the risk of toxicity and/or ADRs, especially in persons with existing renal insufficien‐
cy. To date, there is no accepted standard method that can reliably predict renal function in
paraplegia. Review of the current literature shows that the most widely used CG and MDRD
equations overestimate GFR thus not recommended in paraplegia. Although CL24H better
predicts renal function compared to CLCG and MDRD in paraplegia, unpracticality of collecting
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multiple urine samples as well as the propensity for error from serial collections make this
method clinically unfeasible. Different authors have recommended different modification of
existing methods. Until more studies become available, the following methods can serve as
valuable tools in estimating CLDRUG and renal function in individuals with paraplegia: 0.8 CG,
0.7 MDRD, or CLSCI equations.
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